Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.51 |
| ▸ | HTR2C | P28335 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240288 | 0.91 | HTR2A (0.49) | HTR2AHTR2CKCNH2DRD2MMP2 | |
| SCHEMBL643581 | 0.91 | HTR2A (0.49) | HTR2AHTR2CKCNH2DRD2MMP2 | |
| SCHEMBL28057775 | 0.90 | HTR2A (0.46) | HTR2AHTR2CKCNH2DRD2MMP2 | |
| SCHEMBL28343860 | 0.86 | HTR2A (0.46) | HTR2AHTR2CKCNH2DRD2MMP2 | |
| SCHEMBL5212828 | 0.86 | CYP11B1 (0.49) | HTR2AHTR2CKCNH2DRD2PTGS2 | |
| Hydrochloric Acid SCHEMBL4095644 | 0.85 | CYP11B1 (0.48) | HTR2AHTR2CKCNH2DRD2PTGS2 | |
| Formic Acid SCHEMBL28110710 | 0.83 | HTR2A (0.44) | HTR2AHTR2CKCNH2DRD2MMP2 | |
| SCHEMBL28346650 | 0.80 | HTR2A (0.42) | HTR2AHTR2CKCNH2DRD2MMP2 | |
| SCHEMBL28316867 | 0.79 | HTR2A (0.40) | HTR2AHTR2CKCNH2MMP2MMP13 | |
| SCHEMBL20002842 | 0.79 | HTR6 (0.44) | HTR2AHTR2CKCNH2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720065-A1 | PRMT5 INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024245412-A1 | PRMT5 INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | SERVIER PHARMACEUTICALS LLC | 2021-11-18 | — | — | US | disclosed |
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | SERVIER PHARMACEUTICALS LLC | 2021-11-18 | — | — | US | disclosed |
| EP-3860978-A1 | SMALL MOLECULE MENIN INHIBITORS | The Regents Of The University Of Michigan (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166059-A | Small molecule MENIN inhibitors | 密歇根大学董事会 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020072391-A1 | SMALL MOLECULE MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020072391-A1 | SMALL MOLECULE MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | MEN1, BRCA1, KRAS | HTR2A 951/4885HTR2C 1128/4885KCNH2 3041/4885 |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | HTR2A 630/4885HTR2C 265/4885KCNH2 1439/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | HTR2A 1886/4885HTR2C 1872/4885KCNH2 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.